Literature DB >> 22593612

Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.

Philippe Veron1, Christian Leborgne, Virginie Monteilhet, Sylvie Boutin, Samia Martin, Philippe Moullier, Carole Masurier.   

Abstract

A major impediment to the use of adeno-associated virus (AAV)-mediated gene delivery to muscle in clinical applications is the pre-existing immune responses against the vector. Pre-existing humoral response to different AAV serotypes is now well documented. In contrast, cellular responses to AAV capsid have not been analyzed in a systematic manner, despite the risk of T cell reactivation upon gene transfer. AAV1 has been widely used in humans to target muscle. In this study, we analyzed PBMCs and sera of healthy donors for the presence of AAV1 capsid-specific T cell responses and AAV1 neutralizing factors. Approximately 30% of donors presented AAV1 capsid-specific T cells, mainly effector memory CD8(+) cells. IFN-γ-producing cells were also observed among effector memory CD4(+) cells for two of these donors. Moreover, to our knowledge, this study shows for the first time on a large cohort that there was no correlation between AAV1-specific T cell and humoral responses. Indeed, most donors presenting specific Ig and neutralizing factors were negative for cellular response (and vice versa). These new data raise the question of prescreening patients not only for the humoral response, but also for the cellular response. Clearly, a better understanding of the natural immunology of AAV serotypes will allow us to improve AAV gene therapy and make it an efficient treatment for genetic disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593612     DOI: 10.4049/jimmunol.1200620

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.

Authors:  B Greenberg; J Butler; G M Felker; P Ponikowski; A A Voors; J M Pogoda; R Provost; J Guerrero; R J Hajjar; K M Zsebo
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

2.  Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer.

Authors:  Maxime Carpentier; Stéphanie Lorain; Pascal Chappert; Mélanie Lalfer; Romain Hardet; Dominique Urbain; Cécile Peccate; Sahil Adriouch; Luis Garcia; Jean Davoust; David-Alexandre Gross
Journal:  Mol Ther       Date:  2014-12-10       Impact factor: 11.454

3.  Regulatory and Exhausted T Cell Responses to AAV Capsid.

Authors:  Gwladys Gernoux; James M Wilson; Christian Mueller
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

4.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Authors:  Ashley T Martino; Etiena Basner-Tschakarjan; David M Markusic; Jonathan D Finn; Christian Hinderer; Shangzhen Zhou; David A Ostrov; Arun Srivastava; Hildegund C J Ertl; Cox Terhorst; Katherine A High; Federico Mingozzi; Roland W Herzog
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

5.  Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.

Authors:  Guylène Le Meur; Pierre Lebranchu; Fanny Billaud; Oumeya Adjali; Sébastien Schmitt; Stéphane Bézieau; Yann Péréon; Romain Valabregue; Catherine Ivan; Christophe Darmon; Philippe Moullier; Fabienne Rolling; Michel Weber
Journal:  Mol Ther       Date:  2017-09-19       Impact factor: 11.454

6.  Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity.

Authors:  Laurent Bartolo; Stéphanie Li Chung Tong; Pascal Chappert; Dominique Urbain; Fanny Collaud; Pasqualina Colella; Isabelle Richard; Giuseppe Ronzitti; Jocelyne Demengeot; David A Gross; Federico Mingozzi; Jean Davoust
Journal:  JCI Insight       Date:  2019-06-06

7.  C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice.

Authors:  Jerome Denard; Beatrice Marolleau; Christine Jenny; Tata Nageswara Rao; Hans Jörg Fehling; Thomas Voit; Fedor Svinartchouk
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

8.  Humoral and cell-mediated immune response, and growth factor synthesis after direct intraarticular injection of rAAV2-IGF-I and rAAV5-IGF-I in the equine middle carpal joint.

Authors:  Kyla Ortved; Bettina Wagner; Roberto Calcedo; James Wilson; Deanna Schaefer; Alan Nixon
Journal:  Hum Gene Ther       Date:  2015-03       Impact factor: 5.695

Review 9.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

10.  Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies.

Authors:  Yu-Shan Tseng; Kim Van Vliet; Lavanya Rao; Robert McKenna; Barry J Byrne; Aravind Asokan; Mavis Agbandje-McKenna
Journal:  J Virol Methods       Date:  2016-07-14       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.